ALD Treatments, Research and Clinical Trials

What is the goal of treatment?

Start by asking what is being treated in your or your child’s situation. More than one part of care may be needed at the same time.

Adrenal insufficiency

Replace missing hormones when deficiency is confirmed, with a prescribed daily, illness, and emergency plan. See adrenal health.

Cerebral ALD

Find brain changes early and assess appropriate treatment before further loss of function. See brain monitoring and care.

Myeloneuropathy / adult symptoms

Address pain, stiffness, mobility, bladder and bowel concerns, and daily function. See the AMN guide and women with ALD.

A cerebral treatment should not be assumed to resolve adrenal insufficiency or adult spinal cord and nerve symptoms. Ask which benefits a proposed treatment can realistically offer, and which parts of care will still be needed.

Sources: International ALD recommendations, 2022.

Donor stem cell transplantation

For some people with early cerebral ALD, donor hematopoietic stem cell transplantation can halt disease progression. Timing matters: outcomes are less favorable once disease is advanced. An experienced ALD transplantation team needs to assess the MRI findings, neurological function, donor options, and the person’s overall situation.

Transplantation is a major treatment with serious risks. A referral for assessment is not the same as a decision to proceed. Ask what the team recommends, what alternatives exist, what needs to happen next, and how quickly.

It should not be presented as a cure for every manifestation of ALD or a way to reverse all established injury.

Sources: International ALD recommendations.

United States: SKYSONA

SKYSONA (elivaldogene autotemcel) is FDA-approved for boys ages 4–17 with early, active cerebral ALD who do not have an available HLA-matched donor for an allogeneic stem cell transplant. The goal is to slow neurological decline. Specialists must assess the full eligibility criteria; an ALD diagnosis or a VUS alone does not establish eligibility.

The treatment uses the patient’s own gene-modified blood-forming stem cells and requires conditioning chemotherapy. The label describes accelerated approval, with continued approval potentially dependent on confirmation of clinical benefit. It does not treat ALD-related adrenal insufficiency.

Sources: FDA: SKYSONA · SKYSONA prescribing information on DailyMed · FDA safety update, August 2025.

European Union: Nezglyal

In September 2026, the EU authorized Nezglyal (leriglitazone) for males ages 2–12 with cerebral ALD, brain lesions that do not enhance with gadolinium contrast, and a neurological function score of 0 or 1. Those are specialist-assessed criteria. This indication does not extend to adults or to treatment of AMN.

The authorization is under exceptional circumstances: information is incomplete because of the condition’s rarity, and additional evidence and monitoring are required. It should not be described as a proven way to avoid transplantation. Ask how it fits with any transplant assessment.

Prescribing requires safety monitoring, including liver tests and attention to fluid retention. The label includes a contraindication for current or previous heart failure. Families should discuss risks, evidence limits, and local access with their specialist.

Sources: EMA: current Nezglyal authorization · EMA product information.

Regulatory examples checked November 8, 2026. These U.S. and EU indications concern different patient groups. Confirm the current label and availability where you receive care.

What about diets, oils, or supplements?

Ask the care team what outcome an approach has actually been shown to improve. Lowering a blood marker is not automatically evidence that it prevents neurological symptoms or improves daily function.

The 2022 international consensus found insufficient evidence to support Lorenzo’s oil as a disease-modifying treatment for ALD. Discuss any proposed diet, oil, supplement, or other product with your clinicians, including its evidence, risks, and how it fits with existing care.

Sources: International ALD recommendations.

Research can answer different kinds of questions

Observational studies and registries

Collect information about health, symptoms, or test results. Researchers do not assign a treatment as part of an observational study.

Interventional trials

Assign an intervention and study its effects. Depending on the design, there may be a comparison group, random assignment, or a placebo.

Laboratory and biomarker research

Studies biological processes or measurements that might help explain disease or guide future care. A promising measurement still needs evidence that it is useful for the intended purpose.

The Grey Zone guide discusses one project examining uncertain ABCD1 findings. Other research questions may concern disease progression, treatment outcomes, or daily function. A study’s purpose matters as much as its title.

For a family perspective on current treatment development, read the ALD, AMN and cerebral ALD research we’re watching.

Sources: NIH: clinical research basics · ClinicalTrials.gov: types of studies.

How to find and check a study

Start with ALD Connect’s research listings or ClinicalTrials.gov. Use a study’s unique NCT number to keep track of the same record across websites and conversations.

Look for the condition being studied, age and other eligibility criteria, locations, recruitment status, contact details, and the date the record was last updated. Then confirm the details with the study team and your own clinicians. A listing marked “recruiting” does not guarantee that your local site is enrolling or that you qualify.

ClinicalTrials.gov records are supplied by study sponsors or investigators. Being listed there does not mean the U.S. government has approved the study’s safety or scientific quality.

Sources: ClinicalTrials.gov: study information · ClinicalTrials.gov: limitations of its listings.

What should we look for behind a research headline?

A useful conversation starts with the full study report and the question it was designed to answer. Try these prompts:

• Who was studied? Were participants similar in age, diagnosis, symptoms, and disease stage to the person you are asking about?
• What was measured? A laboratory marker, an MRI change, walking ability, daily function, or another outcome?
• What was the comparison? A randomized control group, standard care, a historical group, or no comparison group?
• For how long? What is known about later benefits, harms, and the need for follow-up?
• What remains uncertain? Ask about the size of the study, missing information, and whether another study is needed to confirm the finding.

Peer review, a published result, regulatory approval, and access to a treatment are different steps. Ask your specialist what the evidence changes for your care now.

Sources: NIH: research process and results · ClinicalTrials.gov: research and approval.

Deciding whether to take part

Research participation is voluntary. Informed consent is a conversation about what the study involves, its risks and possible benefits, alternatives, and what will happen to the information collected. You can ask questions before deciding and throughout the study.

Participants may leave a study. If you are considering leaving, discuss how to do so safely and what clinical follow-up remains important. Some treatments have lasting effects or long-term monitoring needs even after participation ends.

Sources: NIH: informed consent · ClinicalTrials.gov: participation and withdrawal.

Bring the study record or consent information to your own care team. Make room to discuss the commitment as well as the medical question.

Questions about a proposed treatment

• Which manifestation of ALD is this meant to treat, and what is the goal?
• What makes me or my child eligible, and what information is still needed?
• What benefits have been demonstrated in people like us, and what remains uncertain?
• What are the serious short-term and long-term risks?
• What are the alternatives, including continuing the current plan?
• How urgent is the decision, and would a second opinion be useful?
• What other monitoring or treatments will still be needed?
• Who will coordinate treatment, recovery, and long-term follow-up?

A few terms you may hear

Indication

The specific condition and patient group covered by a medicine’s approval.

Allogeneic / autologous

Allogeneic means cells come from a donor. Autologous means the person’s own cells are used.

Conditioning

Treatment given to prepare the body before a stem cell infusion.

Study phase

A stage of drug research. Early phases emphasize safety and initial effects; later studies seek stronger evidence of benefit and harm. Phase numbers do not guarantee success.

Randomized / blinded

Randomized means assignment is by chance. Blinded means participants or researchers may not know which study group someone is in.

Endpoint

An outcome a study measures to answer its research question.

Sources: SKYSONA prescribing information on DailyMed · NIH research basics · ClinicalTrials.gov.

Sources and further reading

The sources below informed this draft. Medical expert review is still pending.

• Engelen and colleagues: international ALD recommendations · Neurology, 2022; care goals and transplantation principles. Current regulatory information is linked separately below.
• FDA: SKYSONA · Current U.S. indication and regulatory documents.
• SKYSONA prescribing information on DailyMed · Eligibility, accelerated approval, warnings, and monitoring.
• FDA: SKYSONA blood-cancer safety update · August 7, 2025.
• EMA: Nezglyal · Current EU authorization, issued September 21, 2026.
• Nezglyal product information · EU indication, precautions, and evidence.
• NIH: clinical research basics · Consent, study phases, benefits, and risks.
• ClinicalTrials.gov: learn about studies · Research design and participation.
• ClinicalTrials.gov: disclaimer · Responsibilities and limits of the registry.
• ALD Connect: clinical trials and research · A starting point for finding study records and research resources.